IBDEI077 ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9421,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,9422,0)
 ;;=203.01^^69^664^98
 ;;^UTILITY(U,$J,358.3,9422,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9422,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,9422,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,9422,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,9423,0)
 ;;=238.6^^69^664^102
 ;;^UTILITY(U,$J,358.3,9423,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9423,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,9423,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,9423,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,9424,0)
 ;;=205.00^^69^664^5
 ;;^UTILITY(U,$J,358.3,9424,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9424,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,9424,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,9424,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,9425,0)
 ;;=205.01^^69^664^4
 ;;^UTILITY(U,$J,358.3,9425,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9425,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,9425,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,9425,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,9426,0)
 ;;=205.10^^69^664^29
 ;;^UTILITY(U,$J,358.3,9426,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9426,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,9426,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,9426,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,9427,0)
 ;;=205.11^^69^664^28
 ;;^UTILITY(U,$J,358.3,9427,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9427,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,9427,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,9427,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,9428,0)
 ;;=289.0^^69^664^52
 ;;^UTILITY(U,$J,358.3,9428,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9428,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,9428,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,9428,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,9429,0)
 ;;=238.4^^69^664^103
 ;;^UTILITY(U,$J,358.3,9429,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9429,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,9429,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,9429,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,9430,0)
 ;;=V58.61^^69^664^124
 ;;^UTILITY(U,$J,358.3,9430,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9430,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,9430,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,9430,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,9431,0)
 ;;=282.49^^69^664^116
 ;;^UTILITY(U,$J,358.3,9431,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9431,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,9431,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,9431,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,9432,0)
 ;;=289.89^^69^664^18
 ;;^UTILITY(U,$J,358.3,9432,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9432,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,9432,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,9432,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,9433,0)
 ;;=238.79^^69^664^85
 ;;^UTILITY(U,$J,358.3,9433,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9433,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,9433,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,9433,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,9434,0)
 ;;=287.30^^69^664^104
 ;;^UTILITY(U,$J,358.3,9434,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9434,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,9434,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,9434,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,9435,0)
 ;;=288.09^^69^664^8
 ;;^UTILITY(U,$J,358.3,9435,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9435,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,9435,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,9435,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,9436,0)
 ;;=284.81^^69^664^15
 ;;^UTILITY(U,$J,358.3,9436,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9436,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,9436,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,9436,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,9437,0)
 ;;=284.89^^69^664^14
 ;;^UTILITY(U,$J,358.3,9437,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9437,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,9437,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,9437,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,9438,0)
 ;;=284.9^^69^664^12
 ;;^UTILITY(U,$J,358.3,9438,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9438,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,9438,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,9438,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,9439,0)
 ;;=289.84^^69^664^117
 ;;^UTILITY(U,$J,358.3,9439,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9439,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,9439,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,9439,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,9440,0)
 ;;=204.02^^69^664^3
 ;;^UTILITY(U,$J,358.3,9440,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9440,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,9440,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,9440,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,9441,0)
 ;;=204.12^^69^664^25
 ;;^UTILITY(U,$J,358.3,9441,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9441,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,9441,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,9441,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,9442,0)
 ;;=204.21^^69^664^112
 ;;^UTILITY(U,$J,358.3,9442,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9442,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,9442,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,9442,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,9443,0)
 ;;=204.20^^69^664^113
 ;;^UTILITY(U,$J,358.3,9443,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9443,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,9443,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,9443,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,9444,0)
 ;;=204.22^^69^664^114
 ;;^UTILITY(U,$J,358.3,9444,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9444,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,9444,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,9444,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,9445,0)
 ;;=203.02^^69^664^100
 ;;^UTILITY(U,$J,358.3,9445,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9445,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,9445,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,9445,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,9446,0)
 ;;=205.02^^69^664^6
 ;;^UTILITY(U,$J,358.3,9446,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9446,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,9446,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,9446,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,9447,0)
 ;;=205.12^^69^664^27
 ;;^UTILITY(U,$J,358.3,9447,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9447,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,9447,1,5,0)
 ;;=5^CML in Relapse
 ;;^UTILITY(U,$J,358.3,9447,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,9448,0)
 ;;=V10.91^^69^664^63
 ;;^UTILITY(U,$J,358.3,9448,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9448,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,9448,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,9448,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,9449,0)
 ;;=V10.91^^69^664^72
 ;;^UTILITY(U,$J,358.3,9449,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9449,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,9449,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,9449,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,9450,0)
 ;;=465.9^^69^665^73
 ;;^UTILITY(U,$J,358.3,9450,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9450,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,9450,1,5,0)
 ;;=5^Uri
 ;;^UTILITY(U,$J,358.3,9450,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,9451,0)
 ;;=462.^^69^665^60
 ;;^UTILITY(U,$J,358.3,9451,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9451,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,9451,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,9451,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,9452,0)
 ;;=466.0^^69^665^3
 ;;^UTILITY(U,$J,358.3,9452,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9452,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,9452,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,9452,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,9453,0)
 ;;=112.1^^69^665^78
 ;;^UTILITY(U,$J,358.3,9453,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9453,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,9453,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,9453,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,9454,0)
 ;;=616.0^^69^665^13
 ;;^UTILITY(U,$J,358.3,9454,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9454,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,9454,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,9454,2)
 ;;=^21925
 ;;^UTILITY(U,$J,358.3,9455,0)
 ;;=599.0^^69^665^74
 ;;^UTILITY(U,$J,358.3,9455,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9455,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,9455,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,9455,2)
 ;;=UTI^124436
 ;;^UTILITY(U,$J,358.3,9456,0)
 ;;=460.^^69^665^45
 ;;^UTILITY(U,$J,358.3,9456,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9456,1,4,0)
 ;;=4^460.
 ;;^UTILITY(U,$J,358.3,9456,1,5,0)
 ;;=5^Nasopharyngitis, Acute
 ;;^UTILITY(U,$J,358.3,9456,2)
 ;;=^26543
 ;;^UTILITY(U,$J,358.3,9457,0)
 ;;=372.30^^69^665^14
 ;;^UTILITY(U,$J,358.3,9457,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9457,1,4,0)
 ;;=4^372.30
 ;;^UTILITY(U,$J,358.3,9457,1,5,0)
 ;;=5^Conjunctivitis
 ;;^UTILITY(U,$J,358.3,9457,2)
 ;;=^27546
 ;;^UTILITY(U,$J,358.3,9458,0)
 ;;=595.9^^69^665^15
 ;;^UTILITY(U,$J,358.3,9458,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9458,1,4,0)
 ;;=4^595.9
 ;;^UTILITY(U,$J,358.3,9458,1,5,0)
 ;;=5^Cystitis
 ;;^UTILITY(U,$J,358.3,9458,2)
 ;;=^30304
 ;;^UTILITY(U,$J,358.3,9459,0)
 ;;=110.1^^69^665^16
 ;;^UTILITY(U,$J,358.3,9459,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9459,1,4,0)
 ;;=4^110.1
 ;;^UTILITY(U,$J,358.3,9459,1,5,0)
 ;;=5^Dermatophytosis Nail
 ;;^UTILITY(U,$J,358.3,9459,2)
 ;;=^33173
 ;;^UTILITY(U,$J,358.3,9460,0)
 ;;=562.11^^69^665^17
